ST Shuangcheng: Injection of biflavonoids obtained Australian Therapeutic Goods Administration approval for listing.

*ST Shuangcheng announced that the company recently received the injection form of bivalirudin marketed permit issued by the Australian Therapeutic Goods Administration. This medication is used to treat patients with moderate to high risk acute coronary syndrome, and can be used in combination with aspirin. Previously, the company had obtained the Drug Registration Certificate issued by the National Medical Products Administration for this medication, and had passed the National Medical Products Administration's evaluation of the consistency in quality and efficacy of the injectable generic drug. Obtaining the Australian marketing permit this time will have a positive impact on the company's expansion into overseas markets and performance improvement. However, the export business of the medication is affected by various factors, and there is uncertainty in terms of sales timing, market size and subsequent expansion progress.